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Abstract  
 
Background: Most trials of patients hospitalised for heart failure focus on breathlessness 
(alveolar pulmonary oedema) but worsening peripheral oedema is also an important 
presentation. We investigated the relationship between the severity of peripheral oedema on 
admission and outcome amongst patients with a primary discharge death or diagnosis of heart 
failure. 
 
Objectives: We tested the hypothesis that severity of peripheral oedema is associated with length 
of hospital stay and mortality.  
 
Methods: Patient variables reported to the National Heart Failure Audit for England & Wales 
between April 2008 and March 2013 were included in this analysis. Peripheral oedema was 
classified as ‘none’, ‘mild’, ‘moderate’ or ‘severe’. Length of stay, mortality during the index 
admission and for up to three years after discharge are reported. 
 
Results: Of 121,214 patients, peripheral oedema on admission was absent in 24%, mild in 24%, 
moderate in 33% and severe in 18%. Median length of stay was, respectively, 6, 7, 9 and 12 days 
(P-<0.001), index admission mortality was 7%, 8%, 10% and 16% (P-<0.001) and  mortality at a 
median follow-up of 344 (IQR 94-766) days was 39%, 46%, 52% and  59%.  In an adjusted 
multi-variable Cox model, the hazard ratio for death was 1.51 for severe (P-<0.001, CI 1.50-
1.53), 1.21 for moderate (P-<0.001, CI 1.20-1.22) and 1.04 (P-<0.001, CI 1.02-1.05) for mild 
peripheral oedema compared to patients without peripheral oedema at presentation.   
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Conclusion: Length of hospital stay and mortality during index admission and after discharge 
increased progressively with increasing severity of peripheral oedema at admission. 
 
Key Words: Acute Heart Failure, Peripheral Oedema, Breathlessness, Mortality.  
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Introduction 
The main symptoms of worsening heart failure are breathlessness, at rest or during slight 
exertion, or worsening peripheral oedema; many patients admitted to hospital will have both.(1)  
Surveys suggest that fewer than 50%,(2, 3), perhaps as few as 16% (4), of patients admitted to 
hospital for heart failure have severe breathlessness at rest, whereas, worsening peripheral 
oedema may be an important reason for admission in >60% of cases.(5, 6) However, clinical 
trials of ‘acute’ heart failure have focussed almost exclusively on breathlessness as a presenting 
symptom and designed with pulmonary oedema as the pathophysiological target.  
 
Pulmonary oedema is not necessarily accompanied by obvious fluid retention and may develop 
within minutes or hours. In the context of heart failure, this is due to a rise in left atrial and 
pulmonary capillary pressure beyond a threshold at which the pulmonary lymphatics can deal 
with increasing pulmonary venous congestion and interstitial pulmonary oedema, resulting in 
accumulation of fluid in the alveoli. This may occur due to displacement of fluid from the 
circulation into the lungs rather than an increase in total body water.(7, 8) Pulmonary oedema is 
often due to an acute coronary syndrome (ACS), cardiac arrhythmia (usually atrial fibrillation 
with rapid ventricular response) or uncontrolled hypertension.(9, 10) Severe breathlessness due to 
alveolar pulmonary oedema is an acute medical emergency that requires treatment within minutes 
but is relatively well served by existing therapies including oxygen, intravenous diuretics and 
nitrates and, perhaps, opiates that can resolve symptoms within minutes or hours. As fluid 
redistribution into the alveoli is the underlying pathophysiological mechanism, vasodilators are, 
at least theoretically, a first-line treatment.(11, 12)  
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Peripheral oedema is due to fluid accumulation and typically develops over days, weeks or even 
months and is often due to a gradual, progressive deterioration in cardiac and renal function. It 
will usually be accompanied by a rise in left atrial pressure, pulmonary venous congestion, 
pulmonary hypertension and right ventricular dysfunction leading to a rise in right atrial pressure. 
It is misleading to think of this problem as acute heart failure in the same way as alveolar 
pulmonary oedema. Treatment delays of a few hours or even days will make little difference to 
symptoms and many patients could be managed without hospital admission. Days or weeks of 
treatment, predominantly with diuretics, are required to correct peripheral oedema. However, low 
blood pressure and renal dysfunction often make these patients difficult to manage. Peripheral 
oedema has been associated with longer lengths of stay and higher risks of re-admission and 
death, although these reports included a relatively small number of patients. (2, 13) 
 
Accordingly, we investigated the clinical characteristics, length of stay and mortality, both during 
the index admission and after discharge, according to severity of peripheral oedema at 
presentation in patients enrolled in National Heart Failure Audit (NHFA) for England & Wales.  
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Methods 
The National Heart Failure Audit (NHFA) was established in 2007 for hospitals in England & 
Wales to assess the quality of care of patients with heart failure by collecting information on their 
presentation, characteristics, specialist input, investigations and management.(14) Information is 
collected on hospitalised patients who had heart failure coded in the first position at death or 
discharge. The number of participating NHS trusts in England and Health Boards in Wales 
increased from 86 (52%) in 2008-9 to 145 in 2012-13 (97%). For this analysis, data were 
collected from April 2008 to March 2013. Patients’ clinical characteristics and medicines at 
discharge were extracted from case notes by staff at each hospital. Left ventricular systolic 
dysfunction was defined as a left ventricular ejection fraction <40% and severity of peripheral 
oedema classified as “none”, “mild”, “moderate” or “severe” by local site staff. Haemoglobin and 
serum creatinine were collected routinely only after 2012. Length of stay and all-cause mortality 
during hospital admission and after discharge were recorded until March 2013 using hospital 
information services and tracking by the Medical Research Information Service using an 
individual’s unique National Health Service number.(15, 16)   
 
The analysis was performed using the Stata/MP 13.1 statistical software (College Station, TX). 
The cohort was stratified into groups according to severity of oedema reported at presentation. 
Continuous data are presented as median with interquartile ranges. Categorical variables are 
presented as counts (percentage). We tested for differences amongst groups by using Chi-squared 
tests for nonparametric data, one-way ANOVA for normally distributed continuous variables and 
Kruskal Wallis test where continuous variables were not normally distributed. Prognostic models 
for all-cause mortality were developed using Cox regression. The proportionality of hazards (PH) 
assumption was verified for all covariates using tests based on Schoenfeld residuals.(17, 18)  
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There was no departure from the PH assumption for any covariate. Cox metrics included the 
hazard ratio (HR), 95% confidence intervals (CI), and pseudo r2 (the square of the correlation 
coefficient of the actual and predicted values of dependent variable). This is a measure of 
goodness of fit.(19) Sensitivity analyses were performed on models determined from the imputed 
data. Multiple imputations with chained equations were used to impute missing data. Ten 
imputations were generated. Study findings are reported in accordance with the Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE) recommendations.(20)  
 
Results 
Of 158,906 administrative records, a diagnosis of heart failure was confirmed by local clinicians 
for 136,790 patients (Supplement Figure 1). Of 121,214 patients considered for this analysis, 
peripheral oedema on admission was reported to be absent in 24%, mild in 25%, moderate in 
33% and severe in 18% (Table 1).  Patients with peripheral oedema tended to be older, were more 
likely to be women and were more likely to have a history of diabetes, hypertension and valve 
disease, although not ischaemic heart disease, but none of these differences was large. Patients 
with severe peripheral oedema were more likely to have symptoms at rest or minimal exertion 
(NYHA Class IV: 56%) compared to those without peripheral oedema (26%). Patients with 
severe peripheral oedema had worse renal function and lower haemoglobin but were less likely to 
have Heart Failure with reduced  ejection fraction (HFrEF). Patients with peripheral oedema were 
less likely to be prescribed angiotensin converting-enzyme inhibitors (ACEi), angiotensin 
receptor blockers (ARB) and beta blockers (BB), but more likely to receive mineralocorticoid 
receptor antagonists (MRA), digoxin, loop and thiazide diuretics (Table 1). 
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Patients who had no peripheral oedema at presentation had shorter length of hospital stay (6 (IQR 
3-13) days compared to 7 ((IQR 3-14), 9 (IQR 5-17) and 12 (IQR 6-21) (P <0.001)) for patients 
with mild, moderate and severe peripheral oedema respectively (Table 1). Mortality both during 
the index admission and after discharge increased progressively as the severity of peripheral 
oedema worsened (Table 2). Mortality during the index admission was 7% for patients without 
peripheral oedema but 16% for those with severe peripheral oedema and mortality at three years 
was 39% compared to 59%. Mortality rates were similar for patients with or without HFrEF or in 
the presence of valve disease (Figure 1). 
 
In univariate analysis, the hazard ratio of death (all-cause at any time) was 1.88 for patients with 
severe (P <0.001, CI 1.81-1.84), 1.47 for moderate (P<0.001, CI 1.44-1.51) and 1.20 (P<0.001, 
CI 1.17-1.23) for mild peripheral oedema when compared to those who had none. In multi-
variable Cox regression analysis, we considered three models for statistical modelling, first on 
original and then on imputed data (Table 3 and Supplement Table 2-3). In Cox model 1 
(Supplement Table 2), mortality was assessed after adjusting for age, sex, NYHA class 
(functional capacity), and prior history of diabetes mellitus, hypertension, ischaemic heart 
disease, valvular heart disease, length of stay during index admission and left ventricular systolic 
dysfunction. The hazard ratio for death increased progressively with worsening severity of 
oedema for both complete and imputed data sets. In Cox model 2 (Supplement Table 3), after 
adjusting for haemoglobin and serum creatinine concentrations in addition to the variables in 
model 1 for the smaller cohort with available laboratory data, the hazard ratios for all-cause 
mortality with increasing severity of peripheral oedema were similar to model 1. In Cox model 3 
(Table 3), further adjusting for medicines at discharge in addition to the nine variables in model 1 
had little impact on the relationship between worsening severity of peripheral oedema and death.  
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Discussion 
Analysis of this large registry suggests that peripheral oedema at admission is common amongst 
patients admitted for heart failure and is associated with many clinical characteristics and 
differences in therapy that portend a poor prognosis. However, none of these clinical features 
appear to account for the worse outcome associated with peripheral oedema. Whether more 
effective treatment of peripheral oedema and its causes can improve outcome is uncertain and 
will remain so until trials targeting this problem are designed and completed. 
 
Although the age-adjusted prognosis of patients with stable chronic heart failure is improving, the 
mortality rate for patients with worsening symptoms and signs requiring admission to hospital 
remains high in our large and contemporary national registry. This is despite high rates of 
implementation of treatments known to be effective for HFrEF.(16) In this audit, 87% of patients 
with HFrEF received either an ACEi or ARB, 77% received a beta-blocker and 40% received an 
MRA compared to 72%, 57% and 32% of patients who had Heart failure with preserved ejection 
fraction (HFpEF) (who had left ventricular ejection greater than 40%). Patients with severe 
peripheral oedema were more likely to have HFpEF with valve disease underlying their heart 
failure, but adjusting for these differences did not account for the association between peripheral 
oedema on outcome.  
 
Apart from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized 
Patients with Heart Failure n= 48,612) and ADHERE (Acute Decompensated Heart Failure 
National, number in derivation cohort = 33,046 and validation cohort 32,229 ) registries, most 
prognostic models for acute heart failure were developed based on relatively small cohorts of 
highly selected patients. (21-23) Both models were designed solely to study in-hospital 
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mortality.(24) In OPTIMIZE-HF, age, race, heart rate, systolic blood pressure, serum creatinine 
and sodium concentrations, heart failure as the primary cause of admission, liver disease, 
previous stroke, peripheral vascular disease, hyperlipidaemia, smoking, HFrEF, chronic 
obstructive pulmonary disease (COPD), ACEi and BB at admission predicted in-hospital 
mortality. In ADHERE, blood urea nitrogen (BUN), serum creatinine and systolic blood pressure 
predicted in hospital mortality.  
 
Only 4,402 patients were followed for up to 90 days beyond discharge in OPTIMIZE-HF. 
Systolic blood pressure was the strongest predictor of death, followed by age, weight, COPD, 
depression, serum sodium and creatinine, liver disease and peripheral oedema.  In a multi-
variable analysis, the hazard ratio for death after discharge for lower extremity oedema was 1.36 
(P 0.019, CI 1.05-1.77)(25), which is similar to our findings. The European Society of 
Cardiology Heart Failure Long-Term Registry enrolled 5,039 patients between 2011 and 2013 
but unfortunately did report the proportion admitted with peripheral oedema.(26) 
 
More data are available for patients enrolled in randomised trials but these are inevitably highly-
selected individuals.(23) A post-hoc analysis of PROTECT study (Placebo-controlled 
Randomized Study of theSelectiveA1 Adenosine Receptor Antagonist Rolofylline for Patients 
Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess 
Treatment Effect on Congestion and Renal Function); age, previous heart failure hospitalization, 
peripheral oedema, SBP, serum sodium, urea, creatinine and albumin were selected for final 
model to predict 180 days mortality. However, in this study no variable had a c-index >0.70, few 
had values >0.60 and peripheral oedema had a c-index of only 0.58 for 30-day mortality and 0.54 
for 180 mortality in univariable analysis (an index of 0.5 reflects an association no better than by 
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chance). A post hoc analysis of the RELAXin in Acute Heart Failure (RELAX-AHF) trial 
classified 1,161 patients into those with no/mild oedema and moderate/severe oedema. Patients 
with moderate/severe oedema had a worse prognosis as compare to no/mild oedema but had 
similar relative but possibly greater absolute benefit from administration of serelaxin. (13)  
 
There are many possible reasons for the higher mortality amongst those with more severe 
peripheral oedema. It is likely that they have higher right atrial pressures, reflecting more severe 
pulmonary hypertension, due in part to more severe left heart disease, more severe right 
ventricular dysfunction and more tricuspid regurgitation. (27) The prognosis of patients with 
heart failure may be more strongly related to right than to left ventricular dysfunction.(28) Thus, 
the severity of peripheral oedema may be a surrogate for more severe right heart disease. 
Moreover, a rise in renal vein pressure may contribute to renal dysfunction, diuretic resistance 
and a worse prognosis and hepatic congestion will impair degradation of aldosterone and reduce 
synthesis of albumin, both of which may exacerbate oedema.(29) Low arterial pressure and renal 
dysfunction and a high prevalence of atrial fibrillation may all confound the effective 
implementation and/or benefits of effective therapies. 
 
Very few sizeable trials have targeted patients with peripheral oedema.(30) In the Ultrafiltration 
versus intravenous diuretics for patients hospitalized for Acutely decompensated HF (UNLOAD; 
n = 200) trial, patients with hypervolemia were randomized to Ultrafiltration (UF) or intravenous 
(IV) diuretics. After 48 hours, net fluid and weight loss was greater in the UF group. A lower 
rehospitalisation rate was observed in those assigned to UF without a significant effect on renal 
function or mortality.(31) In contrast, in the Cardiorenal Rescue Study in Acute Decompensated 
Heart Failure (CARRESS-HF; n = 188) trial, stepped pharmacological therapy and UF were 
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similarly effective at short-term correction of fluid overload but there were more adverse events 
in those assigned to UF and no differences were observed on rehospitalisation or mortality.(32-
34) The Aquapheresis Versus Intravenous Diuretics & Hospitalizations for Heart Failure 
(AVOID-HF; n = 224) is the most recent randomized trial comparing UF and pharmacological 
therapy. (35) During the hospital admission, more fluid was removed by UF but weight loss was 
similar in each arm 72 hours after randomization. During a 90-day follow-up, patients assigned to 
UF had a lower rate of re-hospitalisation for heart failure, although no difference in all-cause 
rehospitalisation or mortality was observed. A large proportion of patients in these trials had 
substantial peripheral oedema (UNLOAD; 80%, CARRESS-HF; not reported, AVOID-HF; 87 
%). In summary, although it is clear that UF can off-load fluid in diuretic-resistant patients and 
might be a useful bridging-procedure to a definitive therapy or recovery, it is unclear whether UF 
substantially alters outcome for patients who have severe irreversible cardiac dysfunction.  
 
Current clinical practice lacks a standardized approach to the classification of ‘acute’ heart 
failure. Classification based on the needs of the patient and choice of therapy is one possible 
approach which may vary according to aetiology, left ventricular ejection, heart rhythm, blood 
pressure, renal function, precipitating factors and the acuity and nature of the presentation.  
However, current clinical practice lacks a standardized approach to evaluate and grade either 
pulmonary or peripheral congestion. Accurate methods of assessing pulmonary congestion are 
impractical for routine clinical use.(36) Pulmonary congestion may be assessed on a chest X-ray 
but has low sensitivity and specificity. Assessment by lung ultrasound may be more sensitive and 
quantitative but use is limited to a few enthusiasts and there is limited experience of its use in 
multi-centre studies.(37) Ultrasound measurement of the inferior vena cava is objective and 
strongly related to prognosis but is rarely used in clinical practice .(38) Objective methods of 
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assessing the severity of peripheral oedema are also rarely employed in clinical practice. Better 
scoring systems and clinal tools are needed for routine clinical assessment and grading of both 
pulmonary and peripheral congestion.  
Limitations 
There are many limitations to this analysis. The severity of peripheral oedema and NYHA class 
were assessed by many clinicians in a semi-quantitative fashion often based on case-note review. 
This could account for the anomaly that some patients were admitted without evidence of either 
severe breathlessness or peripheral oedema. However, some patients will have been admitted 
with other diagnoses and only subsequently had their admission dominated by the development 
of heart failure. Some clinical variables were not collected routinely, such as prior history of heart 
failure, signs of pulmonary congestion,  heart rate, blood pressure, urea and natriuretic peptides, 
although the registry has now started to do so.  Detailed assessments of cardiac function, 
especially of the right heart, by echocardiography or other imaging methods, are not available. 
More general aspects of health such as frailty, mood, social network and cognitive function were 
not collected. In common with other large registries, some data were missing although this was 
mostly driven by the year of collection (older data was more likely to be missing). We used 
multiple imputations to avoid potential bias caused by excluding patients with missing data. 
Heart Failure with Mid-range ejection fraction (HFmrEF) is a recently defined entity in the 
European Society of Cardiology (ESC) 2016 HF guidelines, which encompass those patients who 
have a LVEF of 40-49%, elevated plasma concentrations of natriuretic peptides and either left 
ventricular hypertrophy, left atrial enlargement or diastolic dysfunction. In the NHFA, LVEF is 
simply classified as above or below 40% or not recorded for the majority of patients.  
 
Page 14 of 23  
Conclusion 
Many patients admitted to hospital for worsening heart failure have peripheral oedema. However, 
the term acute heart failure may be misleading when applied to such patients. Peripheral oedema 
often develops over a period of days or weeks and, unless accompanied by severe symptoms at 
rest, does not constitute a medical emergency. Moreover, these patients are unlikely to benefit 
from the acute interventions of short duration that were investigated in recent trials of acute heart 
failure. However, patients with severe peripheral oedema have prolonged hospital stays and a 
poor prognosis. Unfortunately, very few clinical trials have been conducted in this population to 
determine what treatments might address their unmet needs. This analysis provides the rationale 
for designing trials with peripheral oedema as the primary therapeutic target in appropriately 
selected patients.  
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Figures   
 
 
 
Figure 1: Kaplan-Meier survival estimates for all-cause mortality according to severity of 
peripheral oedema for the overall population and four phenotypic groups  
HF; Heart Failure, LVEF; Left ventricular ejection fraction, HFrEF; Heart failure with reduced ejection 
fraction, HFpEF; Heart failure with preserved ejection fraction 
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Tables 
Table 1: Clinical Characteristics and treatment at discharge  
 
Variable Data 
available 
No Oedema Mild Oedema Moderate 
Oedema 
Severe 
Oedema 
P-value 
Numbers 121,214 29,150(24%) 30,587(25%) 39,351(33%) 22,126(18%)  
Age (years) 121,212 
(99.9%) 
77 (67-85) 80 (72-86) 80 (72-86) 79 (70-86) <0.0001 
Women  121,134 
(99.9%) 
11,700  
(40%) 
13,978 
(46%) 
17,345 
(44%) 
8,591 
(39%) 
<0.0001 
Previous DM 117,691 
(97%) 
7,103  
(25%) 
8,879 
(30%) 
12,478 
(33%) 
7,566 
(35%) 
<0.0001 
Previous 
HTN 
116,191 
(96%) 
13,404 
(48%) 
16,375 
(56%) 
21,664 
(58%) 
11,902 
(56%) 
<0.0001 
Previous  
IHD 
115,648 
(95%) 
13,591 
(49%) 
15,140 
(52%) 
19,165 
(51%) 
10,232 
(49%) 
<0.0001 
Previous 
Valve heart 
disease 
113,481 
(94%) 
5,375 
(19%) 
6,555 
(23%) 
9,541 
(26%) 
5,886 
(28%) 
<0.0001 
NYHA Class 117,117(97%) 
Class I 6,449 
(6%) 
4,098 
(15%) 
1,034 
(3%) 
815 
(2%) 
502 
(2%) 
<0.0001 
Class II 19,027 
(16%) 
6,472 
(23%) 
7,274 
(24%) 
4,033 
(11%) 
1,248 
(6%) 
<0.0001 
Class III 50,937 
(43%) 
10,215 
(36%) 
12,998 
(44%) 
20,017 
(53%) 
7,707 
(36%) 
<0.0001 
Class IV 40,704 
(35%) 
7,216 
(26%) 
8,402 
(28%) 
13,264 
(35%) 
11,822 
(56%) 
<0.0001 
Creatinine  
(mmol/L) 
36,961 
(30%) 
104 
(82-139) 
108 
(84-145) 
113 
(87-156) 
126 
(93-174) 
0.0001 
Haemoglobin 
(g/L) 
33,540 
(28%) 
12.5 
(11-14) 
12 
(10.8-13.5) 
12 
(10.6-13.2) 
11.7 
(10.3-13) 
0.0001 
Anaemia ** 
 
33,540 
(28%) 
4,009  
(47%) 
4,454 
(55%) 
6,222 
(59%) 
4,166 
(65%) 
<0.001 
Echocardiogram with LVEF available: 100,313 (83%) 
HFpEF. No 
Valve Dis. 
11,870  2,436  
(10%) 
2,877 
(11%) 
4,151 
(13%) 
2,406 
(13%) 
0.001 
HFrEF. No 
Valve Dis. 
71,670 19,164  
(78%) 
18,253 
(73%) 
22,218 
(69%) 
12,035 
(66%) 
<0.001 
HFpEF & 
Valve Dis. 
11,638 1,967  
(8%) 
2,749 
(11%) 
4,291 
(13%) 
2,631 
(15%) 
<0.001 
HFrEF & 
Valve Dis. 
5,135 1,070 
(4%) 
1,227 
(5%) 
1,672 
(5%) 
1,166 
(6%) 
0.001 
Unknown 
LVEF 
20,309 4,361 
(15%) 
5,338 
(17%) 
6,830 
(17%) 
3,780 
(17%) 
0.001 
Length of 
stay in days 
121,030 
(99.9%) 
6 
(3-13) 
7 
(3-14) 
9 
(5-17) 
12 
(6-21) 
0.0001 
Treatment at discharge 
ACE 
inhibitor 
105,706 
(87%) 
16,971/25,923 
(65%) 
16,699/27,226 
(61%) 
20,172/34,318 
(59%) 
9,994/18,239 
(55%) 
<0.0001 
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ARB 96,269 
(79%) 
3,723/23,324 
(16%) 
4,271/24,894 
(17%) 
5,098/31,386 
(16%) 
2,484/16,665 
(15%) 
<0.0001 
Beta blocker 106,756 
(88%) 
18,565/26,176 
(71%) 
18,143/27,441 
(66%) 
21,705/34,648 
(63%) 
11,184/18,941 
(60%) 
<0.0001 
MRA 105,032 
(87%) 
9,037/25,289 
(36%) 
9,742/26,888 
(36%) 
13,994/34,249 
(41%) 
9,121/18,606 
(49%) 
<0.0001 
Digoxin 104,847 
(86%) 
4,768/25,290 
(19%) 
5,957/26,749 
(22%) 
8,446/34,013 
(25%) 
4,996/18,795 
(27%) 
<0.0001 
Loop 
diuretics 
112,166 
(93%) 
21,872/27,003 
(81%) 
26,012/28,825 
(90%) 
33,715/36,653 
(92%) 
18,113/19,775 
(92%) 
<0.0001 
Thiazide like 
diuretics 
102,484 
(85%) 
564/24,599 
(2%) 
884/26,177 
(3%) 
2,114/33,382 
(6%) 
2,209/18,326 
(12%) 
<0.0001 
 
Data are percentages or median and inter-quartile range. 
All proportions according to severity of oedema in brackets are calculated from available data  
DM; Diabetes Mellitus, g/l; Gram per litre, HTN; Hypertension, IQR; Interquartile range, IHD; Ischaemic 
Heart disease, HFrEF = heart failure and left ventricle ejection fraction < 40%, HFpEF = heart failure and 
left ventricle ejection fraction >40%, NYHA; New York Heart Association, ACI; Angiotensin Converting 
Enzyme Inhibitor, ARB; Angiotensin receptor blocker, MRA; Mineralocorticoid Receptor antagonist. 
** Anaemia = Haemoglobin <13 for men and <12 for women 
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Table 2: Mortality & Univariate Analysis 
Variable No 
Oedema 
Mild Oedema Moderate 
Oedema 
Severe 
Oedema 
P-value 
Numbers 29,150 30,587 39,351 22,126  
Deaths during index 
admission 
2,150 
(7%) 
2,427 
(8%) 
3,981 
(10%) 
3,432 
(16%) 
<0.0001 
Hazard ratio of death 
from discharge to census 
Ref 1.24 
(P <0.0001, CI 
1.21-1.28) 
1.50 
(P<0.0001, CI 
1.46-1.54) 
1.80 
(P<0.0001, CI 
1.75-1.86) 
 
Total deaths 11,507 
(39%) 
13,929 
(46%) 
20,377 
(52%) 
13,003 
(59%) 
<0.0001 
Hazard ratio of death 
from admission to 
census 
Ref 1.20 
(P <0.001, CI 
1.17-1.23) 
1.47 
(P <0.0001, 
1.44-1.51) 
1.88 
(P <0.0001, 
1.84-1.94) 
 
Hazard ratio of death 
from admission to 
census on Imputed data 
Ref 1.15 
(P < 0.0001, 
1.14-1.16) 
1.41 
(P <0.0001  
1.40-1.42) 
1.83 
(P <0.0001 
1.81-1.84) 
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Table 3: Multi Variable Cox Regression Model 3 on original and imputed data 
 Cox Model based on Original data 
(P < 0.0001) 
Cox Model based on Imputed data  
(P < 0.0001) 
Variables Hazard Ratio P-value & CI Hazard Ratio P-value & CI 
Oedema* 
           Mild  1.13 <0.001 
1.09-1.18 
1.06 <0.001 
1.05-1.07 
           Moderate 1.31 <0.001 
1.27-1.37 
1.24 <0.001 
1.22-1.25 
           Severe 1.57 <0.001 
1.51-1.63 
1.55 <0.001 
1.53-1.57 
Age 1.04 <0.001 
1.03-1.05 
1.04 <0.001 
1.03-1.04 
Male Gender 1.13 <0.001 
1.10-1.15 
1.12 <0.001 
1.11-1.13 
NYHA Class+ 
          Class II 1.08 <0.02 
1.01-1.15 
0.90 <0.001 
0.88-0.91 
          Class III 1.22 <0.001 
1.15-1.30 
0.99 <0.81 
0.98-1.01 
          Class IV 1.34 <0.001 
1.26-1.42 
1.17 <0.001 
1.15-1.19 
H/O Diabetes 
Mellitus 
1.08 <0.001 
1.08-1.11 
1.09 <0.001 
1.08-1.10 
H/O Hypertension 0.93 <0.001 
0.90-0.95 
0.91 <0.001 
0.90-0.92 
H/O of IHD 1.25 <0.001 
1.22-1.28 
1.17 <0.001 
1.16-1.18 
H/O Valvular 
heart disease 
1.22 <0.001 
1.18-1.25 
1.21 <0.001 
1.20-1.22 
Length of stay 1.005 <0.001 
1.004-1.006 
1.004 <0.001 
1.003-1.005 
HFrEF 1.21 <0.001 
1.17-1.24 
1.14 <0.001 
1.13-1.15 
ACI 0.58 <0.001 
0.56-0.59 
0.65 <0.001 
0.64-0.66 
ARB 0.57 <0.001 
0.54-0.59 
0.64 <0.001 
0.63-0.65 
MRA 0.95 <0.001 
0.93-0.98 
1.02 <0.001 
1.01-1.03 
Beta blockers 0.70 <0.001 
0.69-0.72 
0.76 <0.001 
0.75-0.77 
Digoxin 0.99 <0.66 
0.97-1.02 
0.93 <0.001 
0.92-0.94 
Loop diuretics 0.70 <0.001 
0.68-0.73 
0.73 <0.001 
0.72-0.74 
Thiazide diuretics 1.26 <0.001 
1.20-1.32 
1.16 <0.001 
1.15-1.18 
* Compare to No Oedema at presentation + Compare to NYHA class 1 at presentation.  
CI; 95% Confidence Interval, H/O; History of, IHD; Ischaemic heart disease, NYHA; New York Heart 
Association,  
